Lamounier-Zepter V, Look C, Schunck W-H, Schlottmann I, Woischwill C, Bornstein S R, Xu A, Morano I
Medical Clinic III, University of Technology Dresden, Dresden, Germany.
Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany.
Int J Obes (Lond). 2015 May;39(5):755-61. doi: 10.1038/ijo.2014.193. Epub 2014 Nov 5.
Adipocyte fatty acid-binding protein (FABP4) is a member of a highly conserved family of cytosolic proteins that bind with high affinity to hydrophobic ligands, such as saturated and unsaturated long-chain fatty acids and eicosanoids. Recent evidence has supported a novel role for FABP4 in linking obesity with metabolic and cardiovascular disorders. In this context, we identified FABP4 as a main bioactive factor released from human adipose tissue that directly suppresses heart contraction in vitro. As FABP4 is known to be a transport protein, it cannot be excluded that lipid ligands are involved in the cardiodepressant effect as well, acting in an additional and/or synergistic way.
We investigated a possible involvement of lipid ligands in the negative inotropic effect of adipocyte factors in vitro.
We verified that blocking the CYP epoxygenase pathway in adipocytes attenuates the inhibitory effect of adipocyte-conditioned medium (AM) on isolated adult rat cardiomyocytes, thus suggesting the participation of epoxyeicosatrienoic acids (EETs) in the cardiodepressant activity. Analysis of AM for EETs revealed the presence of 5,6-, 8,9-, 11,12- and 14,15-EET, whereas 5,6-EET represented about 45% of the total EET concentration in AM. Incubation of isolated cardiomyocytes with EETs in similar concentrations as found in AM showed that 5,6-EET directly suppresses cardiomyocyte contractility. Furthermore, after addition of 5,6-EET to FABP4, the negative inotropic effect of FABP4 was strongly potentiated in a concentration-dependent manner.
These data suggest that adipocytes release 5,6-EET and FABP4 into the extracellular medium and that the interaction of these factors modulates cardiac function. Therefore elevated levels of FABP4 and 5,6-EET in obese patients may contribute to the development of heart dysfunction in these subjects.
脂肪细胞脂肪酸结合蛋白(FABP4)是细胞溶质蛋白高度保守家族的成员,它能与疏水性配体(如饱和及不饱和长链脂肪酸和类花生酸)高亲和力结合。最近的证据支持FABP4在将肥胖与代谢和心血管疾病联系起来方面具有新作用。在此背景下,我们确定FABP4是人类脂肪组织释放的主要生物活性因子,它在体外直接抑制心脏收缩。由于已知FABP4是一种转运蛋白,因此不能排除脂质配体也参与心脏抑制作用,以额外和/或协同的方式发挥作用。
我们研究了脂质配体是否可能参与脂肪细胞因子在体外的负性肌力作用。
我们证实,阻断脂肪细胞中的细胞色素P450环氧化酶途径可减弱脂肪细胞条件培养基(AM)对成年大鼠离体心肌细胞的抑制作用,从而提示环氧二十碳三烯酸(EETs)参与心脏抑制活性。对AM中EETs的分析显示存在5,6-、8,9-、11,12-和14,15-EET,而5,6-EET约占AM中总EET浓度的45%。用与AM中发现的浓度相似的EETs孵育离体心肌细胞表明,5,6-EET直接抑制心肌细胞收缩力。此外,向FABP4中加入5,6-EET后,FABP4的负性肌力作用以浓度依赖性方式强烈增强。
这些数据表明,脂肪细胞将5,6-EET和FABP4释放到细胞外介质中,这些因子的相互作用调节心脏功能。因此,肥胖患者中FABP4和5,6-EET水平升高可能导致这些受试者心脏功能障碍的发生。